Advancedsignaling
Receptor Tyrosine Kinases: Growth Factor Signaling
Overview
Receptor tyrosine kinases are cell-surface receptors that phosphorylate themselves on tyrosine residues when growth factors bind. Dimerization triggers autophosphorylation, creating docking sites for relay proteins that launch cascades like the MAPK pathway. They govern cell division, differentiation, and survival — and when mutated, drive many cancers, making them major drug targets.
Learning objectives
- Describe RTK structure and the dimerization mechanism
- Explain autophosphorylation and docking-site creation
- Trace RTK signaling into the MAPK cascade
- Relate RTK mutations to cancer and targeted therapy
Structure and function
| Part | Structure | Function |
|---|---|---|
| Extracellular ligand-binding domain | Growth-factor docking region | Detects EGF, insulin, PDGF and other signals |
| Single transmembrane helix | Membrane-spanning segment | Anchors the receptor; transmits dimerization |
| Intracellular kinase domain | Tyrosine-phosphorylating enzyme region | Autophosphorylates the dimer partner on tyrosines |
| Phosphotyrosine docking sites | Phosphorylated tyrosine residues | Recruit SH2-domain relay proteins to launch cascades |
| GRB2-SOS complex | Adaptor and exchange factor | Links the receptor to Ras activation |
| Ras-MAPK link | G-protein to kinase cascade entry | Converts receptor signal into the division program |
An RTK signaling diagram: two receptors float separately (inactive); growth factor binding dimerizes them; kinase domains cross-phosphorylate tyrosines (P icons); SH2 relay proteins dock on the phosphotyrosines; GRB2-SOS activates Ras; the Raf→MEK→ERK cascade flows to the nucleus where division genes switch on. A parallel PI3K-Akt branch shows survival signaling. A drug icon blocks the kinase domain labeled 'targeted therapy'.
Built to Dimerize
Each RTK has an extracellular ligand-binding domain, a single transmembrane helix, and an intracellular kinase domain — inactive as a loner. When a growth factor binds, two receptors pair up (dimerize), bringing their kinase domains together. Dimerization is the activation event: alone they are silent, together they fire.
RTKs: single transmembrane helix, dimerize, phosphorylate tyrosines directly, drive growth/division. GPCRs: seven helices, use G-proteins, drive fast metabolic responses. Different architecture, different jobs.
Autophosphorylation: Tagging Themselves
Once dimerized, each kinase phosphorylates tyrosine residues on its partner — autophosphorylation. These phosphotyrosines are not just 'on' markers; they are docking sites, each recruiting specific relay proteins with matching SH2 domains. The pattern of phosphorylated tyrosines encodes which downstream pathways get activated.
From Docking to the MAPK Cascade
Docked relay proteins (like GRB2-SOS) activate Ras, the G-protein switch that launches the Raf → MEK → ERK kinase cascade into the nucleus, switching on division genes. The same receptors can simultaneously trigger PI3K-Akt survival signaling — one dimer, multiple coordinated programs: divide, survive, grow.
Insulin's Receptor Is an RTK
The insulin receptor is a classic RTK: insulin binding triggers autophosphorylation, launching glucose-uptake and metabolic programs. This surprises students who file insulin under 'hormones' and RTKs under 'growth' — the mechanism crosses those categories, showing signaling logic is about chemistry, not labels.
Cancer's Favorite Oncogenes, Medicine's Targets
Mutations that lock RTKs (or downstream Ras) in the 'on' state drive uncontrolled division — EGFR in lung cancer, HER2 in breast cancer. Targeted drugs like erlotinib (EGFR inhibitor) and trastuzumab/Herceptin (anti-HER2 antibody) block exactly these receptors. Understanding RTKs is understanding precision oncology.
Key points
- RTKs have one transmembrane helix and activate by dimerization
- Autophosphorylation on tyrosines creates docking sites
- SH2 relay proteins link receptors to the Ras-MAPK cascade
- One receptor can trigger division, survival, and growth programs
- Mutant RTKs drive cancers; targeted drugs block them
Common misconceptions
✓ Truth: Fundamentally different: RTKs phosphorylate directly after dimerizing (one helix each); GPCRs (seven helices) never phosphorylate — they activate G-proteins. Different machines that sometimes converge on shared downstream cascades.
✓ Truth: RTKs phosphorylate tyrosines, but most cellular phosphorylation is on serine and threonine (by other kinases like PKA and MAPKs). Tyrosine phosphorylation is the RTK specialty, not the general rule.
✓ Truth: RTK signals also control survival (blocking apoptosis), differentiation, migration, and metabolism — insulin's RTK regulates glucose, not growth. 'Growth factor' is a historical name for a versatile signal family.
Practice questions
Q1. RTK activation begins when ligand binding causes receptors to:
- exchange GDP for GTP
- dimerize, bringing kinase domains together
- open an ion channel
- release cAMP
Dimerization positions the two kinase domains to cross-phosphorylate each other. GDP/GTP exchange is the GPCR mechanism; channels and cAMP belong to other signaling modes.
Q2. Autophosphorylated tyrosines on an activated RTK function primarily as:
- energy sources for the cell
- docking sites recruiting SH2-domain relay proteins
- blockers of dimerization
- degradation tags only
Phosphotyrosines are molecular Velcro for SH2-containing relays like GRB2, physically linking the receptor to downstream cascades. They encode which pathways activate, not just that the receptor is on.
Q3. A lung cancer is driven by a mutant EGFR locked in the active state. The most targeted treatment approach is:
- a drug blocking the EGFR kinase domain
- surgical removal of all GPCRs
- increasing cAMP levels
- blocking insulin receptors
Precision oncology targets the specific driver: EGFR kinase inhibitors (like erlotinib) block the mutant receptor's signaling. The other options miss the actual oncogenic mechanism.
Click a question to reveal the answer and explanation.
Frequently asked questions
What is dimerization and why does it matter?
Two receptor monomers pairing up after ligand binding. It brings the kinase domains together so they can phosphorylate each other — the pairing itself is the activation switch. No dimer, no signal.
How does Herceptin treat breast cancer?
Some breast cancers overexpress the HER2 RTK, driving constant division signaling. Trastuzumab (Herceptin) is an antibody that binds HER2's extracellular domain, blocking its signaling and flagging the cell for immune attack.
What are SH2 domains?
Protein modules that specifically recognize and bind phosphotyrosine residues. They are the 'readers' of RTK autophosphorylation, docking relay proteins onto the activated receptor to continue the signal.
Can RTK signaling be turned off?
Yes: phosphatases remove the tyrosine phosphates, receptors are internalized and degraded, and feedback inhibitors damp the cascade. Cancer often results when these off-switches fail alongside stuck-on receptors.